Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrilizumab plus GEMOX for Unresectable Gallbladder Cancer
NCT05919095Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gallbladder cancer, sponsored by Sun Yat-sen Memorial Hospital. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
gallbladder cancer
Beyond the preview
Go deeper on NCT05919095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919095.